Trial Profile
A Randomized Phase II Trial to Evaluate the Immunogenicity and Safety of an Adjuvanted A(H1N1)v Influenza Vaccine and a Non-adjuvanted A(H1N1)v Influenza Vaccine in HIV-infected Patients (ANRS 151 Hifluvac)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 Jul 2022
Price :
$35
*
At a glance
- Drugs Influenza A virus vaccine-H1N1 (Primary) ; AS03A
- Indications Influenza A virus H1N1 subtype
- Focus Adverse reactions; Pharmacodynamics
- Acronyms HIFLUVAC
- Sponsors GSK
- 26 Sep 2012 Results published in AIDS.
- 21 Jan 2011 Actual end date (Dec 2010 ) added as reported by ClinicalTrials.gov.
- 21 Jan 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.